Najla

Skyrocket and Transform Your Real Estate Career at Buffini Master Class in Anaheim, CA on February 8-9, 2024

Retrieved on: 
Tuesday, January 30, 2024
Working, All-star, Life, Senior, Marketing, Consultant, Najla, Diving, Philosophy, PRCP, Buffini, The Wall Street Journal, Los, National Association of Realtors, Astronaut, National Association, Property management

Hosted by founder and chairman Brian Buffini, an esteemed and influential leader in the real estate sector, this Master Class is set to be a career-defining experience.

Key Points: 
  • Hosted by founder and chairman Brian Buffini, an esteemed and influential leader in the real estate sector, this Master Class is set to be a career-defining experience.
  • Discover key strategies and tips from leading industry experts on how to master your real estate business, set and achieve ambitious goals with purpose and create the life and career you envision.
  • Master Class is proud to feature a lineup of distinguished guest speakers who have redefined the various sectors of real estate.
  • Visit Buffini & Company Master Class Registration to register and take the first step toward transforming your career.

Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

Retrieved on: 
Wednesday, January 25, 2023
Other Health, Research, General Health, Professional Services, Mental Health, Small Business, Science, Biotechnology, Alternative Medicine, Finance, Other Science, Health, Therapy, PMA, Najla, MEDI, FRA, NEO, SQ2, Well-being, OTC, Pharmaceutical industry

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate at the upcoming Psychedelic Medicine Association (PMA) Webinar on Thursday, January 26th at 5 pm Pacific, 8 pm Eastern.

Key Points: 
  • Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate at the upcoming Psychedelic Medicine Association (PMA) Webinar on Thursday, January 26th at 5 pm Pacific, 8 pm Eastern.
  • Najla will participate on “Increasing Access to Psychedelic Medicines and Therapies,” panel on January 26th at 5 pm PST/8pm EST.
  • For more information about the webinar, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at [email protected] .

Benzinga Recognizes Women's Impact In Psychedelics By Appointing Six Industry Trailblazers To Its Advisory Council

Retrieved on: 
Thursday, February 2, 2023
The Little Book of Cannabis, Najla, Neurology, MAPS, Multidisciplinary Association for Psychedelic Studies, Policy, Drug Policy Alliance, Global Impact, Yale College, DailyOM, Veteran, CALM, JLS, News, Anesthesia, Software, University, MSW, Education, Growth, Advocacy, Publishing, Community, Mental health, Digital Science, MDMA, Research, Culture, Health, Science, FSE, Citrus, Policy advocacy, New York (magazine), Health equity, Psychiatric Nursing, Drug development, Columbia University, Trauma, Psychiatric-mental health nurse practitioner, Flavonoid, Conference, Lauren, Trauma Center, Social work, CSE, History, Pharmaceutical industry, Nightclub, Drug, Nursing, Cannabis, Guardian

DETROIT, Feb. 2, 2023 /PRNewswire/ -- Benzinga, a financial news and data company, has added 6 new members to its Benzinga Psychedelics Advisory Council .

Key Points: 
  • DETROIT, Feb. 2, 2023 /PRNewswire/ -- Benzinga, a financial news and data company, has added 6 new members to its Benzinga Psychedelics Advisory Council .
  • The council not only recognizes the achievements of industry pioneers but also grants Benzinga readers and conference attendees access to credible, expert analysis.
  • From exclusive articles, expert opinions, and live discussions at the Benzinga Psychedelics Capital Conferences , to informative quotes on relevant news, the Benzinga Psychedelics Advisory Council is your ultimate guide to the psychedelics industry.
  • "Benzinga is a media giant that has dedicated a large amount of real estate to emerging markets, such as cannabis, crypto, and psychedelics.

Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

Retrieved on: 
Wednesday, November 30, 2022
Biotechnology, Alternative Medicine, FDA, Health, General Health, Pharmaceutical, Mental Health, Other Science, Research, Science, Clinical Trials, NEO, European Medicines Agency, Najla, OTC, ASD, FXS, Digital, SQ2, Food, Health Canada, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KGK, Database, Autism, Orphan drug, CGMP, Drug development, Nova, Phases of clinical research, CTA, IIA, Digital Science, Research, Therapy, NOVA, Psilocybin, Science, CSE, Publication, Fragile X syndrome, MEDI, Trial of the century, FRA, Safety, Pharmaceutical industry

This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.

Key Points: 
  • This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.
  • The CTA is subject to a 30-day review by Health Canada, and if approval is granted, KGK intends to start the clinical study in early 2023.
  • The submission of the CTA is a significant milestone in the clinical development of Nova Mentis proprietary drug called NM-1001, said William Rascan, President & CEO of Nova Mentis.
  • Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

Wellbeing Digital Announces Resignation of Directors

Retrieved on: 
Friday, November 18, 2022
Research, Mental Health, Finance, Professional Services, Small Business, Biotechnology, General Health, Health, Science, Other Science, OTC, Drug development, FRA, Najla, Well-being, SQ2, MEDI, Therapy, Growth, NEO, Patient, Pharmaceutical industry, Management

Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company.

Key Points: 
  • Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that James Henning and Steven Inglefield have stepped down as directors of the Company.
  • James has served on the Wellbeing board of directors since the Companys inception, said Najla Guthrie, CEO of Wellbeing.
  • With the Companys decision to divest IRP Health Ltd. (IRP), Steven leaves to focus on IRPs expanding growth.
  • Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.

Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics

Retrieved on: 
Tuesday, October 11, 2022
Research, Mental Health, Finance, Clinical Trials, Professional Services, Small Business, Biotechnology, Alternative Medicine, Health, Science, Digital Science, Therapy, Najla, MEDI, Patient, Drug development, Research, Publication, SQ2, Psychotherapy, Program, Federal, Science, Health Canada, FRA, Clinic, NEO, CEO, KGK, OTC, Alberta Government Telephones, Government, Database, Medicine, Pharmaceutical industry

Albertas new regulations would require that the administration of psychedelic drugs as an adjunct to psychotherapy take place in licensed facilities.

Key Points: 
  • Albertas new regulations would require that the administration of psychedelic drugs as an adjunct to psychotherapy take place in licensed facilities.
  • Clinics will be required to apply for a license before treating patients with psychedelic-assisted psychotherapy for mental health disorders.
  • Albertas new regulations aim to set minimum standards for the safe administration of psychedelic-assisted psychotherapy, said Najla Guthrie, CEO of Wellbeing & KGK Science.
  • Hopefully other provinces will now follow Albertas lead and establish guidelines that may help facilitate expanded access nationally, added Najla.

Wellbeing Subsidiary KGK Science Announces AKL No Objection Status for ProGo® Branded Ingredient from FDA

Retrieved on: 
Thursday, August 25, 2022
Mental Health, Health, Collagen, CEO, OTC, Safety, AKL, Research, Letter, Protein, Achievement, US Foods, MEDI, Comment, Client, Food, NEO, HBC, Quality of life, Goal, SQ2, Database, Digital Science, Publication, FDA, Therapy, NDI, KGK, FRA, Najla, Health, Drug development, Patient, Well-being, CRO, Dietary supplement, Pharmaceutical industry

FDA has responded with a no objection letter, also called an Acknowledgement (AKL) Without Comment Letter.

Key Points: 
  • FDA has responded with a no objection letter, also called an Acknowledgement (AKL) Without Comment Letter.
  • The AKL response letter from FDA for ProGo is the highest safety rating and attestation the Client could have received for its dietary ingredient.
  • This achievement follows on the heels of successful receipt of the same accolades for both CalGo and OmeGo late last year.
  • Consumers and retailers are starting to understand what it means to have an AKL no-objection letter from the FDA.

Wellbeing Digital Sciences Becomes a Founding Sponsor of the Women in Psychedelics Network

Retrieved on: 
Tuesday, May 10, 2022
Board, MEDI, WIP, Drug development, Board of directors, Lead, Woman, RSU, GLOBE, SQ2, Policy, Company, Medicine, Well-being, NEO, Patient, OTC, KGK, FRA, Najla, Therapy, Industry, Publication, Database, Human, Female, Education, Mental health, CEO, Share (finance), Research, Growth, Acquisition, Pharmaceutical industry

Both Wellbeing and its subsidiary, KGK Science Inc. (KGK), are founding supporters of the WIP, as led by Najla Guthrie.

Key Points: 
  • Both Wellbeing and its subsidiary, KGK Science Inc. (KGK), are founding supporters of the WIP, as led by Najla Guthrie.
  • WIP was created to bring women together in the psychedelic industry, of every discipline, and build a community based on education, support, growth, and experience.
  • I am excited for WIP and the value that it is expected to bring to women and the industry.
  • Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research.

Wellbeing Digital Sciences Welcomes Najla Guthrie as Chief Executive Officer

Retrieved on: 
Monday, April 4, 2022
Company, Drug development, Veterans Affairs Canada, Therapy, Veteran, Interim, Post-traumatic stress disorder, Well-being, GAAP, MEDI, Association, FRA, Research, Victoria Wells Wulsin, Publication, KGK, CEO, NEO, IRP, Board of directors, Quality of life, Database, Â, GLOBE, Science, Najla, Cannabis, OTC, Patient, Publishing, SQ2, Management, Pharmaceutical industry

VANCOUVER, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, and its Board of Directors are pleased to welcome Najla Guthrie as its new Chief Executive Officer (CEO) effective March 31, 2022.

Key Points: 
  • VANCOUVER, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, and its Board of Directors are pleased to welcome Najla Guthrie as its new Chief Executive Officer (CEO) effective March 31, 2022.
  • Ms. Guthrie has been the President and CEO of KGK since 1997 and most recently also held the title of Chief Science Officer for Wellbeing.
  • Najla is aptly fitted for her new role as CEO of Wellbeing and is highly regarded in the research, science, and leadership communities.
  • Wellbeing Digital Sciences Inc. is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research.

Wellbeing Digital Sciences Reports Financial Results for the Second Fiscal Quarter of 2022

Retrieved on: 
Friday, March 18, 2022
Total, Company, Health, Drug development, Stop-loss policy, Veterans Affairs Canada, Veteran, Interim, Marketing, Digital Science, Growth, Clinical trial, MEDI, SEDAR, FRA, Addition, Research, Ketamine, Communication, KGK, Science, NEO, IRP, Reactive programming, Consolidated, Capital market, VW, VAC, Patient, New, Technology, Period, Natural health product, COVID-19, GLOBE, Safe, News, Najla, Cannabis, OTC, SQ2, Pharmaceutical industry, Cryptocurrency, Management, Medical device

VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that it has filed its financial results for the quarter ended January 31, 2022, which is the second quarter of the Companys 2022 fiscal year ending July 31, 2022, the highlights of which are included in this news release.

Key Points: 
  • VANCOUVER, British Columbia, March 18, 2022 (GLOBE NEWSWIRE) -- Wellbeing Digital Sciences Inc. (Wellbeing or the Company) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that it has filed its financial results for the quarter ended January 31, 2022, which is the second quarter of the Companys 2022 fiscal year ending July 31, 2022, the highlights of which are included in this news release.
  • The second quarter of fiscal 2022 marked our first financial period as Wellbeing Digital Sciences, which began an exciting new chapter for the Company.
  • As previously announced, our very own Najla Guthrie will become Chief Executive Officer of the Company effective March 31, 2022.
  • Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research.